Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer therapy will mainly rely on specific targets ...
Hosted on MSN9mon
Enabling rapid screening of poly(2-oxazoline)-based nanomedicine through divergent synthesisReactive end-groups on non-immunogenic biocompatible polymers, such as PEG ... while avoiding premature blood clearance and off-target toxicity. The installment of a biocompatible "stealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback